HSP90 inhibition enhances cancer immunotherapy by upregulating interferon response genes

HSP90 inhibition enhances cancer immunotherapy by upregulating interferon response genes

Many patients fail to respond to T cell based immunotherapies. Here, the authors, through a high-throughput screening, identify HSP90 inhibitors as a class of preferred drugs for treatment combination with immunotherapy.

Bibliographic Details
Main Authors: Rina M. Mbofung, Jodi A. McKenzie, Shruti Malu, Min Zhang, Weiyi Peng, Chengwen Liu, Isere Kuiatse, Trang Tieu, Leila Williams, Seram Devi, Emily Ashkin, Chunyu Xu, Lu Huang, Minying Zhang, Amjad H. Talukder, Satyendra C. Tripathi, Hiep Khong, Nikunj Satani, Florian L. Muller, Jason Roszik, Timothy Heffernan, James P. Allison, Gregory Lizee, Sam M. Hanash, David Proia, Rodabe Amaria, R. Eric Davis, Patrick Hwu
Format: Article
Language:English
Published: Nature Publishing Group 2017-09-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/s41467-017-00449-z

Similar Items

Similar Items